Results 211 to 220 of about 34,737 (245)
Some of the next articles are maybe not open access.
The Journal of Infectious Diseases, 1990
The treatment of opportunistic infections in AIDS patients is changing rapidly as new drugs become available and new studies of old drugs are completed. I have tried to use the AIDS commentaries to keep up with these advances. Since fluconazole has just recently been approved by the US Food and Drug Administration, I asked Dr. Robert A.
openaire +2 more sources
The treatment of opportunistic infections in AIDS patients is changing rapidly as new drugs become available and new studies of old drugs are completed. I have tried to use the AIDS commentaries to keep up with these advances. Since fluconazole has just recently been approved by the US Food and Drug Administration, I asked Dr. Robert A.
openaire +2 more sources
Journal of Infection, 2015
Azole-resistance in Aspergillus fumigatus is emerging and is becoming an increasing problem in the management of aspergillosis. Two types of development of resistance have been described; resistance acquired during azole treatment in an individual patient and through environmental exposure to fungicides. The main molecular mechanism of azole resistance
openaire +2 more sources
Azole-resistance in Aspergillus fumigatus is emerging and is becoming an increasing problem in the management of aspergillosis. Two types of development of resistance have been described; resistance acquired during azole treatment in an individual patient and through environmental exposure to fungicides. The main molecular mechanism of azole resistance
openaire +2 more sources
Seminars in Respiratory and Critical Care Medicine, 2008
This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use.
Dimitrios I, Zonios, John E, Bennett
openaire +2 more sources
This is a comprehensive, clinically oriented review of the four commercially available triazoles: fluconazole, itraconazole, voriconazole, and posaconazole. Emphasis is placed in pharmacology, drug interactions, adverse events, antifungal activity, and the evolving perspective of their clinical use.
Dimitrios I, Zonios, John E, Bennett
openaire +2 more sources
Clinical Infectious Diseases, 1992
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +2 more sources
The discovery of the antifungal activity of azole compounds represented an important therapeutic advance. Miconazole, ketoconazole, and fluconazole are currently commercially available, and itraconazole has undergone extensive clinical evaluation. Because of its limited activity and toxicity, miconazole has been replaced by newer agents.
openaire +2 more sources
Energetic Azolium Azolate Salts
Inorganic Chemistry, 2005Energetic salts comprising substituted imidazolium and 1,2,4-triazolium cations and 4,5-dinitro-imidazolate and 5-nitrotetrazolate anions were synthesized and characterized. On the basis of experimentally obtained heats of combustion, the calculated heats of formation range from deltaHf(o) degrees = 80 (3) to 1071 kJ/mol (13).
Hong, Xue +3 more
openaire +2 more sources
Sulfonyl Azoles in the Synthesis of 3-Functionalized Azole Derivatives
The Chemical Record, 2016Sulfonyl indoles, as well as related azolyl derivatives, have been recently introduced in synthesis as stable precursors of reactive indolenine intermediates. This personal account reports on the discovery of sulfonyl azoles and their practical utilization in many synthetic processes for the preparation of functionalized 3-substituted indoles ...
PALMIERI, Alessandro, PETRINI, Marino
openaire +2 more sources
Médecine et Maladies Infectieuses, 1984
Resume Les premiers azoles antifongiques possedent un spectre d'activite restreint. L'etonam (R 10100) etait actif contre les dermatophytes a la fois in vitro et in vivo par application topique. Le spectre antimycosique dans le traitement topique s'est elargi avec le miconazole et le clotrimazole.
J. Van Cutsem, P.A.J. Janssen
openaire +1 more source
Resume Les premiers azoles antifongiques possedent un spectre d'activite restreint. L'etonam (R 10100) etait actif contre les dermatophytes a la fois in vitro et in vivo par application topique. Le spectre antimycosique dans le traitement topique s'est elargi avec le miconazole et le clotrimazole.
J. Van Cutsem, P.A.J. Janssen
openaire +1 more source
Therapie, 2006
Azoles have maintained a key role in the treatment of invasive fungal infections which have a growing importance, especially in immunocompromised patients. Because of its good activity and safety, fluconazole has becoming the treatment of choice for invasive candidiasis, except those caused by Candida glabrata and C. krusei.
Michel, Wolff +2 more
openaire +2 more sources
Azoles have maintained a key role in the treatment of invasive fungal infections which have a growing importance, especially in immunocompromised patients. Because of its good activity and safety, fluconazole has becoming the treatment of choice for invasive candidiasis, except those caused by Candida glabrata and C. krusei.
Michel, Wolff +2 more
openaire +2 more sources